Axonics Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retent… Read more
Axonics Inc (0I3) - Net Assets
Latest net assets as of June 2024: €643.32 Million EUR
Based on the latest financial reports, Axonics Inc (0I3) has net assets worth €643.32 Million EUR as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€747.34 Million) and total liabilities (€104.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €643.32 Million |
| % of Total Assets | 86.08% |
| Annual Growth Rate | N/A |
| 5-Year Change | 248.39% |
| 10-Year Change | N/A |
| Growth Volatility | 22.03 |
Axonics Inc - Net Assets Trend (2016–2023)
This chart illustrates how Axonics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Axonics Inc (2016–2023)
The table below shows the annual net assets of Axonics Inc from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €637.56 Million | +11.83% |
| 2022-12-31 | €570.14 Million | +18.18% |
| 2021-12-31 | €482.44 Million | +67.88% |
| 2020-12-31 | €287.37 Million | +57.03% |
| 2019-12-31 | €183.00 Million | +27.73% |
| 2018-12-31 | €143.28 Million | +315.71% |
| 2017-12-31 | €-66.42 Million | -34.37% |
| 2016-12-31 | €-49.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axonics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33124690800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.02 Billion | 159.66% |
| Total Equity | €637.56 Million | 100.00% |
Axonics Inc Competitors by Market Cap
The table below lists competitors of Axonics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baic Bluepark New Energy Technology
SHG:600733
|
$3.29 Billion |
|
Kintetsu Group Holdings Co.Ltd
F:KKI
|
$3.29 Billion |
|
GlobalWafers Co Ltd
TWO:6488
|
$3.29 Billion |
|
Mapletree Logistics Trust
PINK:MAPGF
|
$3.29 Billion |
|
TERNS PHARMACEUT.DL-0001
F:430
|
$3.29 Billion |
|
Gerdau S.A
SA:GGBR3
|
$3.29 Billion |
|
KANDENKO CO. LTD
F:5EY
|
$3.29 Billion |
|
Industrias Penoles Sab De CV
PINK:IPOAF
|
$3.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axonics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 570,139,000 to 637,564,000, a change of 67,425,000 (11.8%).
- Net loss of 6,088,000 reduced equity.
- Other factors increased equity by 73,513,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.09 Million | -0.95% |
| Other Changes | €73.51 Million | +11.53% |
| Total Change | €- | 11.83% |
Book Value vs Market Value Analysis
This analysis compares Axonics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-2.62 | €63.50 | x |
| 2018-12-31 | €5.15 | €63.50 | x |
| 2019-12-31 | €5.36 | €63.50 | x |
| 2020-12-31 | €7.20 | €63.50 | x |
| 2021-12-31 | €10.41 | €63.50 | x |
| 2022-12-31 | €11.51 | €63.50 | x |
| 2023-12-31 | €12.56 | €63.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axonics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.66%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.13x
- Recent ROE (-0.95%) is above the historical average (-14.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | €-12.46 Million |
| 2017 | 0.00% | -14097.05% | 0.00x | 0.00x | €-11.42 Million |
| 2018 | -22.67% | -4594.48% | 0.00x | 1.20x | €-46.81 Million |
| 2019 | -43.68% | -578.40% | 0.06x | 1.20x | €-98.24 Million |
| 2020 | -19.11% | -49.24% | 0.33x | 1.19x | €-83.65 Million |
| 2021 | -16.60% | -44.41% | 0.33x | 1.14x | €-128.31 Million |
| 2022 | -10.47% | -21.81% | 0.42x | 1.16x | €-116.71 Million |
| 2023 | -0.95% | -1.66% | 0.51x | 1.13x | €-69.84 Million |
Industry Comparison
This section compares Axonics Inc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axonics Inc (0I3) | €643.32 Million | 0.00% | 0.16x | $3.29 Billion |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |